Cambrex Corporation Company Profile (NYSE:CBM)

About Cambrex Corporation

Cambrex Corporation logoCambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities. The Company's manufacturing facilities are located in the Europe and the United States. The Company's business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company's products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and other fine chemicals. The Company's products and services are sold around the world under trademarks that are owned by the Company. This includes Profarmaco, which is registered around the world as a word and design mark. Its products are sold through a combination of direct sales and independent agents.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NYSE
  • Symbol: CBM
  • CUSIP: 13201110
Key Metrics:
  • Previous Close: $54.30
  • 50 Day Moving Average: $54.12
  • 200 Day Moving Average: $48.61
  • 52-Week Range: $32,346,000.00 - $36.24
  • Trailing P/E Ratio: 21.92
  • Foreward P/E Ratio: 16.72
  • P/E Growth: 1.20
  • Market Cap: $1.76B
  • Outstanding Shares: 32,346,000
  • Beta: 1.95
  • Net Margins: 16.65%
  • Return on Equity: 24.53%
  • Return on Assets: 15.94%
  • Current Ratio: 3.38%
  • Quick Ratio: 2.09%
Additional Links:
Companies Related to Cambrex Corporation:

Analyst Ratings

Consensus Ratings for Cambrex Corporation (NYSE:CBM) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $65.67 (20.82% upside)

Analysts' Ratings History for Cambrex Corporation (NYSE:CBM)
DateFirmActionRatingPrice TargetDetails
2/6/2017StephensSet Price TargetBuy$61.00View Rating Details
2/6/2017Craig HallumSet Price TargetBuy$70.00View Rating Details
1/17/2017First AnalysisBoost Price TargetOverweight$54.00 -> $66.00View Rating Details
2/11/2016Singular ResearchLower Price TargetBuy$63.00 -> $60.00View Rating Details
2/1/2016SidotiInitiated CoverageBuy$60.00View Rating Details
7/31/2015Longbow ResearchReiterated RatingBuy$48.00 -> $60.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Cambrex Corporation (NYSE:CBM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/3/2017Q416$1.05$1.23$174.53 million$178.70 millionViewListenView Earnings Details
11/4/2016Q3$0.41$0.47$96.07 million$99.90 millionViewListenView Earnings Details
7/28/2016Q216$0.59$0.68$114.85 million$118.22 millionViewListenView Earnings Details
4/29/2016Q116$0.34$0.50$83.61 million$94.74 millionViewListenView Earnings Details
2/9/2016Q4$0.83$0.54$152.94 million$156.90 millionViewListenView Earnings Details
11/3/2015Q3$0.38$0.40$101.09 million$92.97 millionViewListenView Earnings Details
7/30/2015Q215$0.44$0.63$110.03 million$106.40 millionViewListenView Earnings Details
5/1/2015Q115$0.23$0.29$76.01 million$78.20 millionViewListenView Earnings Details
2/6/2015Q414$0.50$0.64$117.90 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.26$0.28$94.25 million$81.10 millionViewListenView Earnings Details
8/12/2014$0.21$0.32ViewN/AView Earnings Details
8/1/2014Q214$0.28$0.35$92.70 million$98.00 millionViewListenView Earnings Details
5/2/2014Q114$0.23$0.07$79.40 million$66.20 millionViewListenView Earnings Details
2/11/2014Q4$0.30$0.30$95.25 million$103.00 millionViewListenView Earnings Details
11/1/2013Q313$0.21$0.20$83.60 million$78.00 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.26$0.10$73.70 million$61.60 millionViewListenView Earnings Details
5/3/2013Q1 2013$0.22$0.36$76.15 million$74.58 millionViewListenView Earnings Details
2/6/2013Q4 2012$0.13$0.26$68.30 million$69.93 millionViewListenView Earnings Details
11/5/2012Q312$0.12$0.07$61.00 million$59.21 millionViewN/AView Earnings Details
8/1/2012$0.21$0.33ViewN/AView Earnings Details
5/3/2012$0.14$0.24ViewN/AView Earnings Details
2/6/2012$0.12$0.10ViewN/AView Earnings Details
11/3/2011$0.07$0.10ViewN/AView Earnings Details
8/2/2011$0.13$0.16ViewN/AView Earnings Details
5/5/2011$0.08$0.10ViewN/AView Earnings Details
2/10/2011$0.10$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cambrex Corporation (NYSE:CBM)
Current Year EPS Consensus Estimate: $3.01 EPS
Next Year EPS Consensus Estimate: $3.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.25$0.25$0.25
Q2 20161$0.48$0.48$0.48
Q3 20162$0.40$0.45$0.43
Q4 20162$0.93$1.07$1.00
Q1 20172$0.48$0.51$0.50
Q2 20172$0.71$0.78$0.75
Q3 20172$0.51$0.52$0.52
Q4 20172$1.20$1.25$1.23
(Data provided by Zacks Investment Research)


Dividend History for Cambrex Corporation (NYSE:CBM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Cambrex Corporation (NYSE:CBM)
Insider Ownership Percentage: 2.63%
Institutional Ownership Percentage: 98.23%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/16/2017Steven M KloskCEOSell23,822$52.50$1,250,655.00View SEC Filing  
2/13/2017Steven M KloskCEOSell63,178$52.55$3,320,003.90View SEC Filing  
2/7/2017Gregory SargenEVPSell30,000$54.88$1,646,400.00View SEC Filing  
2/7/2017Shawn CavanaghCOOSell20,380$55.12$1,123,345.60View SEC Filing  
12/14/2016Shawn CavanaghCOOSell30,000$53.58$1,607,400.00View SEC Filing  
11/11/2016Gregory SargenInsiderSell22,500$52.02$1,170,450.00View SEC Filing  
7/11/2016William B KorbDirectorSell3,420$55.00$188,100.00View SEC Filing  
6/8/2016William B KorbDirectorSell4,142$52.47$217,330.74View SEC Filing  
6/1/2016William B KorbDirectorSell8,000$51.06$408,480.00View SEC Filing  
5/9/2016Steven M KloskCEOSell14,005$49.00$686,245.00View SEC Filing  
5/5/2016Steven M KloskCEOSell16,430$49.13$807,205.90View SEC Filing  
5/3/2016William B KorbDirectorSell8,000$49.09$392,720.00View SEC Filing  
3/16/2016Steven M KloskCEOSell19,565$41.00$802,165.00View SEC Filing  
3/15/2016Louis J GrabowskyDirectorBuy750$40.10$30,075.00View SEC Filing  
3/10/2016William B KorbDirectorSell8,000$41.38$331,040.00View SEC Filing  
2/11/2016Gregory SargenCFOSell13,622$36.16$492,571.52View SEC Filing  
2/11/2016Shawn CavanaghCOOSell18,342$36.13$662,696.46View SEC Filing  
2/11/2016Steven M. KloskCEOSell39,542$36.20$1,431,420.40View SEC Filing  
12/15/2015Leon J. Hendrix, Jr.DirectorSell7,000$51.34$359,380.00View SEC Filing  
12/11/2015Peter G. TombrosDirectorSell31,236$51.37$1,604,593.32View SEC Filing  
11/30/2015Ilan KaufthalDirectorSell52,315$54.32$2,841,750.80View SEC Filing  
11/13/2015Gregory SargenCFOSell28,750$49.14$1,412,775.00View SEC Filing  
11/6/2015Samantha HanleyVPSell15,000$52.03$780,450.00View SEC Filing  
8/27/2015William B. KorbDirectorSell3,600$48.00$172,800.00View SEC Filing  
5/21/2015Ilan KaufthalDirectorSell50,000$41.31$2,065,500.00View SEC Filing  
5/11/2015Gregory SargenCFOSell25,000$38.44$961,000.00View SEC Filing  
2/12/2015Aldo MagniniDirectorSell7,500$32.75$245,625.00View SEC Filing  
2/12/2015Gregory SargenCFOSell25,000$32.64$816,000.00View SEC Filing  
2/10/2015Steven M KloskCEOSell45,000$30.32$1,364,400.00View SEC Filing  
9/11/2014Shawn CavanaghCOOSell56,251$22.56$1,269,022.56View SEC Filing  
9/3/2014Steven M KloskCEOSell126,257$22.01$2,778,916.57View SEC Filing  
9/2/2014William M HaskelSVPSell9,400$21.94$206,236.00View SEC Filing  
8/19/2014Steven M KloskCEOSell4,702$22.00$103,444.00View SEC Filing  
8/7/2014Steven M KloskCEOSell1,200$22.52$27,024.00View SEC Filing  
8/7/2014William M HaskelSVPSell28,100$22.50$632,250.00View SEC Filing  
8/5/2014Gregory SargenCFOSell50,000$22.34$1,117,000.00View SEC Filing  
2/28/2014Leon Hendrix, Jr.DirectorSell23,000$20.09$462,070.00View SEC Filing  
2/20/2014Aldo MagniniDirectorSell6,000$22.10$132,600.00View SEC Filing  
12/5/2013Paolo RussoloInsiderSell35,000$18.40$644,000.00View SEC Filing  
11/11/2013Gregory SargenCFOSell20,000$18.92$378,400.00View SEC Filing  
11/11/2013John MillerDirectorSell2,000$19.21$38,420.00View SEC Filing  
5/24/2013Paolo RussoloInsiderSell32,903$12.53$412,274.59View SEC Filing  
5/16/2013Leon J Hendrix JrDirectorSell1,120$13.40$15,008.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Cambrex Corporation (NYSE:CBM)
DateHeadline logoCambrex Corp. breached its 50 day moving average in a Bullish Manner : CBM-US : February 17, 2017 (NYSE:CBM) - February 17 at 6:00 PM logoCambrex: A Pure Growth Play - Seeking Alpha (NYSE:CBM) - February 16 at 4:14 PM logoCambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conference (NYSE:CBM) - February 16 at 9:01 AM
News IconStock Sheet: Reviewing the Levels for Cambrex Corporation (NYSE:CBM) - Davidson Register (NYSE:CBM) - February 14 at 4:50 PM logoETFs with exposure to Cambrex Corp. : February 14, 2017 (NYSE:CBM) - February 14 at 4:50 PM
News IconStock Watch & Analyst Take on Cambrex Corporation (NYSE:CBM) - Rockville Register (NYSE:CBM) - February 14 at 2:49 AM logoCambrex Corp. :CBM-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 (NYSE:CBM) - February 8 at 4:26 PM logoCAMBREX CORP Financials (NYSE:CBM) - February 8 at 4:26 PM logoCambrex Corp. :CBM-US: Earnings Analysis: Q4, 2016 By the Numbers : February 7, 2017 (NYSE:CBM) - February 7 at 5:14 PM logoCambrex Corp.: Leads amongst peers with strong fundamentals (NYSE:CBM) - February 6 at 9:12 PM
News IconStock Price of Cambrex Corporation (CBM) Increases 9.29% - Morning Outlook (NYSE:CBM) - February 6 at 4:11 PM logo6:48 am Cambrex beats by $0.19, beats on revs; issues 2017 guidance (NYSE:CBM) - February 5 at 4:09 PM
News IconCambrex Q4 Profit Tops Estimates; Sales Up 14% (NYSE:CBM) - February 4 at 4:15 PM
News IconCambrex Corporation (CBM) Releases Earnings Results, Beats Expectations By $0.19 EPS (NYSE:CBM) - February 4 at 4:15 PM
News IconAnalysts Update Their Price Target On Cambrex Corporation (NYSE:CBM) (NYSE:CBM) - February 4 at 4:15 PM
News IconCambrex (NYSE:CBM) 4Q16 Profit Up 22%; Beats Street View (NYSE:CBM) - February 4 at 2:25 AM logoEdited Transcript of CBM earnings conference call or presentation 3-Feb-17 1:30pm GMT (NYSE:CBM) - February 3 at 9:25 PM logoCambrex Q4 Profit Tops Estimates; Sales Up 14% - Quick Facts (NYSE:CBM) - February 3 at 4:23 PM logoCambrex Corporation (CBM) Jumps on Earnings Estimate (NYSE:CBM) - February 3 at 4:23 PM
News IconCambrex Corporation Reports Fourth Quarter And Full Year 2016 Financial Results (NYSE:CBM) - February 3 at 4:23 PM logoCAMBREX CORPORATION (NYSE:CBM) Files An 8-K Results of Operations and Financial Condition (NYSE:CBM) - February 3 at 4:23 PM logoCambrex Corp. (CBM) Has Surged To A New High On Strong Q4 Results (NYSE:CBM) - February 3 at 4:23 PM logoCambrex posts 4Q profit (NYSE:CBM) - February 3 at 4:23 PM logoQ4 2016 Cambrex Corp Earnings Release - Before Market Open (NYSE:CBM) - February 3 at 4:23 PM logoCambrex Reports Fourth Quarter and Full Year 2016 Financial Results (NYSE:CBM) - February 3 at 8:25 AM logoCambrex beats by $0.18, beats on revenue (NYSE:CBM) - February 3 at 6:58 AM logoCambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017 (NYSE:CBM) - February 1 at 4:27 PM
News IconTechnical Buzz on Cambrex Corporation (NYSE:CBM) - The Tribune (NYSE:CBM) - January 29 at 2:20 AM
News IconFollowing FCF Scores for Cambrex Corporation (NYSE:CBM) - The Tribune (NYSE:CBM) - January 27 at 5:25 PM logoCleantech Building Materials: LOAN CONVERSION AND ISSUE OF NEW SHARES (NYSE:CBM) - January 27 at 5:25 PM
News IconStock to Watch: Cambrex Corporation. (CBM) - Springdale Times (NYSE:CBM) - January 25 at 5:14 PM logoCambrex Corp. – Value Analysis (NYSE:CBM) : January 25, 2017 (NYSE:CBM) - January 25 at 5:14 PM
News IconChecking the Piotroski Score on Shares of Cambrex Corporation (NYSE:CBM) - The Tribune (NYSE:CBM) - January 24 at 9:45 PM logoCambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : January 24, 2017 (NYSE:CBM) - January 24 at 4:43 PM logoCambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : January 24, 2017 (NYSE:CBM) - January 24 at 4:43 PM
News IconRating Sentiment To Observe: Here's how analysts see Cambrex Corporation (NYSE:CBM) after this past week. - Fair View Times (NYSE:CBM) - January 19 at 1:20 AM
News IconCambrex Corporation (CBM) Stock Down After Price Target Increase at First Analysis - The Ledger Gazette (NYSE:CBM) - January 18 at 3:17 PM
News IconCambrex Corp CBM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NYSE:CBM) - January 12 at 9:31 PM
News IconEqis Capital Management buys $3,903,592 stake in Cambrex ... - Highland Mirror (NYSE:CBM) - January 12 at 2:38 AM
News IconStock in Focus: Cambrex Corporation (NYSE:CBM) - Wall Street Beacon (NYSE:CBM) - January 9 at 12:34 AM logoAmgen's Repatha Wins Over Sanofi & Regeneron's Praluent (NYSE:CBM) - January 6 at 9:33 PM logoCAMBREX CORPORATION (NYSE:CBM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive (NYSE:CBM) - January 6 at 4:32 PM logoCAMBREX CORPORATION (NASDAQ:CBM) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NYSE:CBM) - January 6 at 4:32 PM logoCambrex Corporation (NYSE:CBM) Held $43.974 In Cash And Short-Term Investments ... (NYSE:CBM) - January 5 at 9:35 PM logoEvoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III (NYSE:CBM) - January 5 at 4:34 PM logoOcular (OCUL) Reports Positive Phase III Data on Eye Drug (NYSE:CBM) - January 5 at 4:34 PM
News IconInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Announces Top-line Results for MATrX-1 (NYSE:CBM) - January 4 at 5:11 PM logo6:32 am Cambrex appoints Tom Vadaketh as CFO effective Jan 20, 2017; current CFO Greg Sargen will transition to a newly-created role, Executive VP, Corporate Development & Strategy (NYSE:CBM) - January 4 at 5:11 PM logoCAMBREX CORP Files SEC form 8-K, Change in Directors or Principal Officers (NYSE:CBM) - January 4 at 5:11 PM logoCambrex Appoints Tom Vadaketh as Executive Vice President and Chief Financial Officer (NYSE:CBM) - January 4 at 5:11 PM


What is Cambrex Corporation's stock symbol?

Cambrex Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Where is Cambrex Corporation's stock going? Where will Cambrex Corporation's stock price be in 2017?

3 analysts have issued 1 year price targets for Cambrex Corporation's stock. Their predictions range from $61.00 to $70.00. On average, they anticipate Cambrex Corporation's share price to reach $65.67 in the next twelve months.

When will Cambrex Corporation announce their earnings?

Cambrex Corporation is scheduled to release their next quarterly earnings announcement on Thursday, April, 27th 2017.

Who owns Cambrex Corporation stock?

Cambrex Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (6.43%), Dimensional Fund Advisors LP (4.19%), Congress Asset Management Co. MA (3.30%), State Street Corp (2.13%), Ranger Investment Management L.P. (1.96%) and FMR LLC (1.56%). Company insiders that own Cambrex Corporation stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix, Jr, Louis J Grabowsky, Peter G Tombros, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb.

Who sold Cambrex Corporation stock? Who is selling Cambrex Corporation stock?

Cambrex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management AG, Marshall Wace LLP, Century Capital Management LLC, Fiera Capital Corp, Guggenheim Capital LLC, AQR Capital Management LLC, Ranger Investment Management L.P. and Systematic Financial Management LP. Company insiders that have sold Cambrex Corporation stock in the last year include Gregory Sargen, Shawn Cavanagh, Steven M Klosk and William B Korb.

Who bought Cambrex Corporation stock? Who is buying Cambrex Corporation stock?

Cambrex Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Russell Investments Group Ltd., FMR LLC, Columbia Wanger Asset Management LLC, Two Sigma Investments LP, State Street Corp, William Blair Investment Management LLC and Foresters Investment Management Company Inc..

How do I buy Cambrex Corporation stock?

Shares of Cambrex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cambrex Corporation stock cost?

One share of Cambrex Corporation stock can currently be purchased for approximately $54.35.

Cambrex Corporation (NYSE:CBM) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Earnings History Chart

Earnings by Quarter for Cambrex Corporation (NYSE:CBM)

Dividend History Chart

Dividend Payments by Quarter for Cambrex Corporation (NYSE:CBM)

Last Updated on 2/19/2017 by Staff